Migraine Disorders

Neurology
16
Pipeline Programs
6
Companies
21
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
0
4
0
6
2
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

Eli Lilly and Company
REYVOWApproved
lasmiditan
Eli Lilly and Company
oral2019

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Teva
TevaIsrael - Petach Tikva
3 programs
1
1
1
Fremanezumab Prefilled Syringe [Ajovy]Phase 41 trial
NP101Phase 34 trials
Sumatriptan succinatePhase 12 trials
Active Trials
NCT00723983Completed23Est. Sep 2009
NCT00846885Completed28Est. Oct 2004
NCT00806546Completed514Est. May 2011
+4 more trials
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
2 programs
1
1
1
REYVOW(Lasmiditan)Phase 21 trial
LY2951742Phase 11 trial
Active Trials
NCT02104765Completed45Est. Jan 2015
NCT00883051Completed512Est. Feb 2010
Alder Therapeutics
Alder TherapeuticsSweden - Solna
5 programs
1
1
2
ALD403Phase 31 trial
ALD403Phase 31 trial
ALD403Phase 21 trial
ALD403Phase 11 trial
A Pilot Study of Migraine and Appetite Behaviour in ChildrenN/A1 trial
Active Trials
NCT00930852Completed60Est. Aug 2010
NCT01579383Completed104Est. Apr 2013
NCT02275117Completed665Est. Nov 2016
+2 more trials
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
5 programs
1
2
2
Low dose ASAPhase 31 trial
MetamizolPhase 31 trial
BI 44370 TA Low DosePhase 21 trial
BIBN 4096 BSPhase 21 trial
BI 44370 TA tabletPhase 11 trial
Active Trials
NCT00743015Completed19
NCT00751803Completed416
NCT02198339Completed126
+2 more trials
Abbott
AbbottABBOTT PARK, IL
1 program
1
PFO Closure with Premere investigational device.Phase 31 trial
Active Trials
NCT00267371Terminated168Est. Mar 2012
Pfizer
PfizerNEW YORK, NY
1 program
Reliability of Rimegepant or Triptans for the Acute Treatment of MigraineN/A1 trial
Active Trials
NCT06412965Completed528Est. Jan 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
TevaFremanezumab Prefilled Syringe [Ajovy]
Alder TherapeuticsALD403
Alder TherapeuticsALD403
TevaNP101
TevaNP101
TevaNP101
AbbottPFO Closure with Premere investigational device.
Boehringer IngelheimMetamizol
Boehringer IngelheimLow dose ASA
Alder TherapeuticsALD403
Eli Lilly and CompanyLasmiditan
Boehringer IngelheimBI 44370 TA Low Dose
Boehringer IngelheimBIBN 4096 BS
Eli Lilly and CompanyLY2951742
Alder TherapeuticsALD403

Showing 15 of 21 trials with date data

Clinical Trials (21)

Total enrollment: 8,287 patients across 21 trials

NCT04693533TevaFremanezumab Prefilled Syringe [Ajovy]

Fremanezumab, Migraine and Sleep

Start: Jul 2021Est. completion: Apr 202422 patients
Phase 4Terminated
NCT02974153Alder TherapeuticsALD403

Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine

Start: Nov 2016Est. completion: Apr 20181,121 patients
Phase 3Completed
NCT02559895Alder TherapeuticsALD403

A Multicenter Assessment of ALD403 in Frequent Episodic Migraine

Start: Sep 2015Est. completion: Dec 2017898 patients
Phase 3Completed
NCT00806546TevaNP101

An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months

Start: Feb 2009Est. completion: May 2011514 patients
Phase 3Completed
NCT00792103TevaNP101

An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months

Start: Jan 2009Est. completion: Sep 2010198 patients
Phase 3Completed
NCT00724815TevaNP101

The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine

Start: Jan 2009Est. completion: Jul 2009530 patients
Phase 3Completed
NCT00267371AbbottPFO Closure with Premere investigational device.

ESCAPE Migraine Trial

Start: Nov 2005Est. completion: Mar 2012168 patients
Phase 3Terminated
NCT02183220Boehringer IngelheimMetamizol

Efficacy and Tolerability of Metamizol in Patients With Episodic Moderate Headache

Start: Oct 1998417 patients
Phase 3Completed
NCT02183688Boehringer IngelheimLow dose ASA

Acetylsalicylic Acid (ASA) + Paracetamol + Caffeine Combination Compared With ASA + Paracetamol as Well as ASA, Paracetamol, and Caffeine in Headache Patients

Start: Sep 19981,889 patients
Phase 3Completed
NCT02275117Alder TherapeuticsALD403

A Multicenter Assessment of ALD403 in Chronic Migraine

Start: Oct 2014Est. completion: Nov 2016665 patients
Phase 2Completed
NCT00883051Eli Lilly and CompanyLasmiditan

Dose-ranging Study of Oral COL-144 in Acute Migraine Treatment

Start: Jul 2009Est. completion: Feb 2010512 patients
Phase 2Completed
NCT00751803Boehringer IngelheimBI 44370 TA Low Dose

BI 44370 TA in Acute Migraine Attack

Start: Aug 2008416 patients
Phase 2Completed
NCT02198339Boehringer IngelheimBIBN 4096 BS

Efficacy, Safety, Tolerability and Pharmacokinetics of BIBN 4096 BS Versus Placebo in the Treatment of a Single Attack of Acute Migraine Headache

Start: Feb 1999126 patients
Phase 2Completed
NCT02104765Eli Lilly and CompanyLY2951742

A Study of LY2951742 in Healthy Japanese and Caucasian Participants

Start: Jun 2014Est. completion: Jan 201545 patients
Phase 1Completed
NCT01579383Alder TherapeuticsALD403

Safety Tolerability and Pharmacokinetics of ALD403

Start: Apr 2012Est. completion: Apr 2013104 patients
Phase 1Completed
NCT00723983TevaSumatriptan succinate

Phase I, Open Label, Single-Dose, Four Way Crossover Study to Compare the PK of NP101 With Oral Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period

Start: Nov 2008Est. completion: Sep 200923 patients
Phase 1Completed
NCT00743015Boehringer IngelheimBI 44370 TA tablet

Relative Bioavailability of a Single Dose of BI 44370 Tablet During and Between Migraine Attacks

Start: Sep 200819 patients
Phase 1Completed
NCT00720018TevaNP101

Phase I Open Label Single-Dose Study to Compare the Pharmacokinetics of NP101 Healthy Volunteers

Start: Jun 2008Est. completion: Jul 20084 patients
Phase 1Completed
NCT00846885TevaSumatriptan succinate

Sumatriptan Succinate 100 mg Tablets Under Non-Fasting Conditions

Start: Aug 2004Est. completion: Oct 200428 patients
Phase 1Completed
NCT06412965PfizerReliability of Rimegepant or Triptans for the Acute Treatment of Migraine

Reliability of Rimegepant or Triptans for the Acute Treatment of Migraine

Start: Jan 2024Est. completion: Jan 2024528 patients
N/ACompleted
NCT00930852Alder TherapeuticsA Pilot Study of Migraine and Appetite Behaviour in Children

A Pilot Study of Migraine and Appetite Behaviour in Children

Start: Jul 2009Est. completion: Aug 201060 patients
N/ACompleted

Related Jobs in Neurology

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
4h ago
$208K - $234K/yr

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
4h ago

Director of Medical Affairs

CoMind
Miami, FL
4h ago

Director of Finance

CoMind
London, UK
4h ago

Electronics Engineering Manager

CoMind
London, UK
4h ago

Director of Information Technology

Zavation Medical Products
4h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 late-stage (Phase 3) programs — potential near-term approvals
6 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)